All In Biotech

Drug Trial Radar · NCT05126888

SCI-110 in the Treatment of Tourette Syndrome

A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome.

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Oct 2027

Study completion Feb 2028

Sponsor

Lead sponsor
Neurothera Labs Inc.Industry
Sponsor type
Industry
First posted
Nov 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy, safety and tolerability of the cannabinoid-based medication SCI-110 compared to placebo in subjects with Tourette syndrome.

Conditions

  • Tourette Syndrome

Interventions

  • SCI-110Drug

    SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.

  • PlaceboOther

    Pill that matches in taste, odour and appearance to SCI-110 active pills

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change from baseline in revised version of Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS)Time frame: At baseline and 12 weeks after start of treatment in both arms.

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Yale Child Study Center - NIHB 205

    New Haven, Connecticut

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Neurological Institute, Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.